CHM Stock Overview
Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies in oncology in Australia.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Chimeric Therapeutics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.029 |
| 52 Week High | AU$0.073 |
| 52 Week Low | AU$0.023 |
| Beta | 1.72 |
| 1 Month Change | 0% |
| 3 Month Change | 3.57% |
| 1 Year Change | -59.15% |
| 3 Year Change | -89.06% |
| 5 Year Change | n/a |
| Change since IPO | -90.17% |
Recent News & Updates
Shareholder Returns
| CHM | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | -14.7% | 1.9% | 0.9% |
| 1Y | -59.2% | -7.7% | 5.6% |
Return vs Industry: CHM underperformed the Australian Biotechs industry which returned -7.7% over the past year.
Return vs Market: CHM underperformed the Australian Market which returned 5.6% over the past year.
Price Volatility
| CHM volatility | |
|---|---|
| CHM Average Weekly Movement | 11.4% |
| Biotechs Industry Average Movement | 11.4% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in AU Market | 17.6% |
| 10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: CHM's share price has been volatile over the past 3 months.
Volatility Over Time: CHM's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | n/a | Jennifer Chow | www.chimerictherapeutics.com |
Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies in oncology in Australia. The company develops CHM 0201 (core NK platform) that is in phase I clinical trial for treating solid tumors and hematological malignancies; and CHM 1101 (CLTX CAR T), which is in phase I clinical trial for treating patients with MMP2+ recurrent or progressive glioblastoma. It is also developing CHM 0301 for blood cancers; CHM 1301 (CLTX CAR NK) and CHM 2301 (CDH17 CAR NK) for solid tumors; CHM 1101 (CLTX CAR T) for melanoma, colorectal, and prostate; and CHM 2101 (CDH17 CAR T) for neuroendocrine, colorectal, pancreatic, and gastric.
Chimeric Therapeutics Limited Fundamentals Summary
| CHM fundamental statistics | |
|---|---|
| Market cap | AU$24.70m |
| Earnings (TTM) | -AU$11.73m |
| Revenue (TTM) | AU$12.47m |
2.0x
P/S Ratio-2.1x
P/E RatioIs CHM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CHM income statement (TTM) | |
|---|---|
| Revenue | AU$12.47m |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$12.47m |
| Other Expenses | AU$24.19m |
| Earnings | -AU$11.73m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.014 |
| Gross Margin | 100.00% |
| Net Profit Margin | -94.06% |
| Debt/Equity Ratio | 0% |
How did CHM perform over the long term?
See historical performance and comparison